Q1 2026 · 13F-HR
5AM Venture Management, LLCholdings as filed
Filed 2026-05-15 · accession 0001799883-26-000002
$360.2M
Reported value
20
Positions
2026-03-31
Period end
The Brief · 5AM Venture Management, LLC · Q1 2026
AI · grounded in 13F
5AM Venture Management, LLC exited its position in Viridian Therapeutics Inc VRDN, reducing its exposure by $22.9M. The fund also closed its position in Enliven Therapeutics Inc ELVN for $11.9M. To offset these exits, the fund established new positions in Alx Oncology Hldgs Inc ALXO and RallyBio Corp RLYB, investing $6.1M and $2.6M respectively.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 29479A108 | ERAS | ERASCA INC | $56.4M | 15.7% | 3,485,971 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $51.2M | 14.2% | 4,056,379 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $39.4M | 10.9% | 1,029,298 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $25.9M | 7.19% | 5,869,091 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $23.1M | 6.41% | 580,945 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $22.5M | 6.26% | 797,600 | Common | SOLE |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $19.3M | 5.36% | 950,011 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $18.8M | 5.21% | 606,660 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $15.8M | 4.38% | 497,270 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $15.2M | 4.21% | 2,353,304 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT INC | $13.5M | 3.76% | 1,050,000 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $11.3M | 3.13% | 387,500 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $9.2M | 2.56% | 3,947,913 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $8.1M | 2.24% | 572,665 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $7.1M | 1.98% | 1,369,782 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $6.3M | 1.74% | 738,972 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $6.1M | 1.70% | 3,057,325 | Common | SOLE |
| 83086J200 | SKYE | SKYE BIOSCIENCE INC | $6.0M | 1.65% | 9,681,763 | Common | SOLE |
| 75120L209 | RLYB | RALLYBIO CORP | $2.6M | 0.73% | 291,788 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $2.5M | 0.70% | 476,200 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.